Zandra 5 mg/100 ml (IV Infusion)
Medicine Details
| Category | Details |
|---|---|
| Generic | Zoledronic acid for osteoporosis |
| Company | Healthcare pharmaceuticals ltd |
Title
Zandra - Bisphosphonate Preparations
Categories
- Medicine
- Healthcare
- Pharmaceuticals
Description
Zandra is indicated for treatment and prevention of postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, treatment and prevention of glucocorticoid-induced osteoporosis, and treatment of Paget’s disease of bone in men and women. It is a bisphosphonate that acts primarily on bone by inhibiting osteoclast-mediated bone resorption. The recommended dosage regimen varies for different conditions and patient groups, and it must be administered as an intravenous infusion over no less than 15 minutes. Zoledronic Acid can cause fetal harm and should not be given to nursing women. It has important administration instructions and specific contraindications, precautions, warnings, and storage conditions. Zandra belongs to the therapeutic class of bisphosphonate preparations.
Related Brands
- Bonizol 5 mg/100 ml (IV Infusion) - square-pharmaceuticals-plc
- Zoltero 5 mg/100 ml (IV Infusion) - beximco-pharmaceuticals-ltd
- Zoledron 5 mg/100 ml (IV Infusion) - opsonin-pharma-ltd
- Zolenic 5 mg/100 ml (IV Infusion) - incepta-pharmaceuticals-ltd
- Aclasta 5 mg/100 ml (IV Infusion) - sandoz-a-novartis-division